Crossmark

Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced, resectable esophageal squamous cell carcinoma: clinical study and mechanistic exploration

Crossref DOI link: https://doi.org/10.1038/s41698-025-01248-2

Published Online: 2026-01-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Hui

Jiang, Qi

Li, Xiaodan

Ye, Peng

Rusidanmu, Aizemaiti

Li, Ning

Teng, Xiaodong

Wang, Qiyue

Chen, Yinqi

Huang, Dongdong

Han, Yuejun

Wang, Bingnan

Yu, Wenhong

Tao, Jian

Ruan, Jian

Jiang, Haiping
Funding

Funding for this research was provided by:

Natural Science Foundation of Zhejiang Province (LMS25H160019)

Development Center for Medical Science and Technology National Health Commission of the People’s Republic of China (WKZX2024CX102213)
License Information

Text and Data Mining valid from 2026-01-17

Version of Record valid from 2026-02-27
More Information

Article History

Received: 15 August 2025

Accepted: 11 December 2025

First Online: 17 January 2026

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below